These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

325 related items for PubMed ID: 16982289

  • 21. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF, Hsiao FY, Wen YW, Tsai YW.
    Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
    [Abstract] [Full Text] [Related]

  • 22. Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin.
    Brinker A, Goldkind L, Bonnel R, Beitz J.
    Drugs Aging; 2004 Nov; 21(7):479-84. PubMed ID: 15132714
    [Abstract] [Full Text] [Related]

  • 23. [COX-2 inhibitors--one step forward and two steps back].
    Evensen S, Spigset O, Slørdal L.
    Tidsskr Nor Laegeforen; 2005 Apr 07; 125(7):875-8. PubMed ID: 15815733
    [Abstract] [Full Text] [Related]

  • 24. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.
    Am J Manag Care; 2002 Oct 07; 8(15 Suppl):S414-27. PubMed ID: 12416791
    [Abstract] [Full Text] [Related]

  • 25. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.
    Am J Manag Care; 2002 Oct 07; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [Abstract] [Full Text] [Related]

  • 26. Selective COX-2 inhibitors, NSAIDs and congestive heart failure: differences between new and recurrent cases.
    McGettigan P, Han P, Jones L, Whitaker D, Henry D.
    Br J Clin Pharmacol; 2008 Jun 07; 65(6):927-34. PubMed ID: 18384446
    [Abstract] [Full Text] [Related]

  • 27. Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study.
    Moride Y, Ducruet T, Boivin JF, Moore N, Perreault S, Zhao S.
    Arthritis Res Ther; 2005 Jun 07; 7(2):R333-42. PubMed ID: 15743481
    [Abstract] [Full Text] [Related]

  • 28. Safety of Etoricoxib, Celecoxib, and Nonselective Nonsteroidal Antiinflammatory Drugs in Ankylosing Spondylitis and Other Spondyloarthritis Patients: A Swedish National Population-Based Cohort Study.
    Kristensen LE, Jakobsen AK, Askling J, Nilsson F, Jacobsson LT.
    Arthritis Care Res (Hoboken); 2015 Aug 07; 67(8):1137-49. PubMed ID: 25623277
    [Abstract] [Full Text] [Related]

  • 29. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
    Hochberg MC.
    Clin Exp Rheumatol; 2001 Aug 07; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
    [Abstract] [Full Text] [Related]

  • 30. Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib.
    Patterson MK, Castellsague J, Walker AM.
    Pharmacoepidemiol Drug Saf; 2008 Oct 07; 17(10):982-8. PubMed ID: 18711705
    [Abstract] [Full Text] [Related]

  • 31. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.
    Senna G, Bilò MB, Antonicelli L, Schiappoli M, Crivellaro MA, Bonadonna P, Dama AR.
    Eur Ann Allergy Clin Immunol; 2004 Jun 07; 36(6):215-8. PubMed ID: 15329003
    [Abstract] [Full Text] [Related]

  • 32. Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective Cyclooxygenase 2 inhibitors: a class effect?
    Hudson M, Rahme E, Richard H, Pilote L.
    Arthritis Rheum; 2007 Apr 15; 57(3):516-23. PubMed ID: 17394181
    [Abstract] [Full Text] [Related]

  • 33. Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs.
    Quiralte J, Delgado J, Sáenz de San Pedro B, López-Pascual E, Nieto MA, Ortega N, Florido JF, Conde J.
    Ann Allergy Asthma Immunol; 2004 Oct 15; 93(4):360-4. PubMed ID: 15521372
    [Abstract] [Full Text] [Related]

  • 34. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
    Spalding WM, Reeves MJ, Whelton A.
    Am J Ther; 2007 Oct 15; 14(1):3-12. PubMed ID: 17303969
    [Abstract] [Full Text] [Related]

  • 35. Was the thrombotic risk of rofecoxib predictable from the French Pharmacovigilance Database before 30 September 2004?
    Sommet A, Grolleau S, Bagheri H, Lapeyre-Mestre M, Montastruc JL, French Network of Regional Pharmacovigilance Centres.
    Eur J Clin Pharmacol; 2008 Aug 15; 64(8):829-34. PubMed ID: 18509626
    [Abstract] [Full Text] [Related]

  • 36. Non-steroidal anti-inflammatory drug-related hepatic damage in France and Spain: analysis from national spontaneous reporting systems.
    Lapeyre-Mestre M, de Castro AM, Bareille MP, Del Pozo JG, Requejo AA, Arias LM, Montastruc JL, Carvajal A.
    Fundam Clin Pharmacol; 2006 Aug 15; 20(4):391-5. PubMed ID: 16867024
    [Abstract] [Full Text] [Related]

  • 37. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study.
    Hudson M, Richard H, Pilote L.
    BMJ; 2005 Jun 11; 330(7504):1370. PubMed ID: 15947399
    [Abstract] [Full Text] [Related]

  • 38. Are rofecoxib and celecoxib safer NSAIDS?
    Drug Ther Bull; 2000 Nov 11; 38(11):81-6. PubMed ID: 11138599
    [Abstract] [Full Text] [Related]

  • 39. Adverse Drug Events Involving COX-2 Inhibitors.
    Verrico MM, Weber RJ, McKaveney TP, Ansani NT, Towers AL.
    Ann Pharmacother; 2003 Sep 11; 37(9):1203-13. PubMed ID: 12921500
    [Abstract] [Full Text] [Related]

  • 40. Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.
    Chen LC, Ashcroft DM.
    Pharmacoepidemiol Drug Saf; 2007 Jul 11; 16(7):762-72. PubMed ID: 17457957
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.